MajesTEC-7 — Teclistamab or talquetamab plus daratumumab and lenalidomide versus daratumumab-lenalidomide-dexamethasone in transplant-ineligible newly diagnosed multiple myeloma (MajesTEC-7)

Phase 3 · Multiple Myeloma

Population

Newly diagnosed multiple myeloma in patients ineligible or not intended for autologous stem cell transplant.

Primary Endpoint

Progression-free survival

Rationale

BCMA and GPRC5D bispecific antibodies produce deep responses in relapsed myeloma. MajesTEC-7 moves them into the front line for transplant-ineligible patients, testing whether adding a T-cell engager to a daratumumab backbone beats today's standard triplet.

What It Could Change

Could bring bispecific T-cell engagers into first-line myeloma therapy for transplant-ineligible patients, redefining the standard of care.